BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12394253)

  • 1. The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomas.
    Eucker J; Schille C; Schmid P; Jakob C; Schetelig J; Kingreen D; Mergenthaler HG; Huhn D; Possinger K; Sezer O
    Anticancer Drugs; 2002 Oct; 13(9):907-13. PubMed ID: 12394253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma.
    Lazzarino M; Orlandi E; Montillo M; Tedeschi A; Pagnucco G; Astori C; Corso A; Brusamolino E; Simoncini L; Morra E; Bernasconi C
    Ann Oncol; 1999 Jan; 10(1):59-64. PubMed ID: 10076723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
    Hendry L; Bowen A; Matutes E; Swansbury J; Catovsky D
    Leuk Lymphoma; 2004 May; 45(5):945-50. PubMed ID: 15291353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma.
    Rao R; Shammo JM; Enschede SH; Porter C; Adler SS; Venugopal P; Gregory SA
    Clin Lymphoma; 2005 Jun; 6(1):26-30. PubMed ID: 15989703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas.
    Lossos IS; Paltiel O; Polliack A
    Leuk Lymphoma; 1999 Mar; 33(1-2):155-60. PubMed ID: 10194133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas.
    Bocchia M; Bigazzi C; Marconcini S; Forconi F; Marotta G; Algeri R; Lauria F
    Haematologica; 1999 Aug; 84(8):716-20. PubMed ID: 10457407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
    Lü SQ; Yang JM; Song XM; Chen L; Zhang WP; Ni X; Xu XQ; Wang JM
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):710-2. PubMed ID: 18246806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group.
    Dimopoulos MA; Fountzilas G; Papageorgiou E; Kiamouris C; Mantzios G; Anagnostopoulos A; Nicolaides C; Economopoulos T;
    Leuk Lymphoma; 2002 Jan; 43(1):111-4. PubMed ID: 11908713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up--a report from the Eastern Cooperative Oncology Group.
    Hochster HS; Oken MM; Winter JN; Gordon LI; Raphael BG; Bennett JM; Cassileth PA
    J Clin Oncol; 2000 Mar; 18(5):987-94. PubMed ID: 10694548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
    Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
    J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.
    Klasa RJ; Meyer RM; Shustik C; Sawka CA; Smith A; Guévin R; Maksymiuk A; Rubinger M; Samosh M; Laplante S; Grenier JF
    J Clin Oncol; 2002 Dec; 20(24):4649-54. PubMed ID: 12488409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma.
    Santini G; Nati S; Spriano M; Gallamini A; Pierluigi D; Congiu AM; Truini M; Rubagotti A; Chisesi T; Vimercati R; Rossi E; Sertoli MR; Mattei D; Marino G; Gobbi M
    Haematologica; 2001 Mar; 86(3):282-6. PubMed ID: 11255275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies.
    Foussard C; Colombat P; Maisonneuve H; Berthou C; Gressin R; Rousselet MC; Rachieru P; Pignon B; Mahé B; Ghandour C; Desablens B; Casassus P; Lamy T; Delwail V; Deconinck E
    Ann Oncol; 2005 Mar; 16(3):466-72. PubMed ID: 15695500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Bendandi M; Tura S
    Eur J Haematol; 1995 Oct; 55(4):262-6. PubMed ID: 7589345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen.
    Gregory SA; Vose J; Modiano M; Kraemer K; Rifkin R; Rubin A; Menduni T; Ghalie R
    Leuk Lymphoma; 2001 Jan; 40(3-4):315-24. PubMed ID: 11426553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma.
    Fabbri A; Lenoci M; Gozzetti A; Chitarrelli I; Olcese F; Raspadori D; Gobbi M; Lauria F
    Br J Haematol; 2007 Oct; 139(1):90-3. PubMed ID: 17854311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.
    Morris GJ; Millenson MM; Padavic-Shaller K; Wang H; Rogatko A; Clyde J; Boyd RL; Yeslow G; Halbherr T; Schilder RJ; Smith MR
    Haematologica; 2004 Dec; 89(12):1484-91. PubMed ID: 15590399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.
    Pro B; Hagemeister FB; McLaughlin P; Romaguera J; Rodriguez MA; Cabanillas F; Tiongson LP; Younes A
    Leuk Lymphoma; 2006 Sep; 47(9):1818-21. PubMed ID: 17064994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
    Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
    Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas.
    Zinzani PL; Magagnoli M; Bendandi M; Gherlinzoni F; Orcioni GF; Cellini C; Stefoni V; Pileri SA; Tura S
    Ann Oncol; 2000 Mar; 11(3):363-5. PubMed ID: 10811507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.